Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444764 | 1.00 | MTNR1A (0.63) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL6982719 | 1.00 | MTNR1A (0.63) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL11484008 | 0.94 | MTNR1A (0.56) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL28716707 | 0.89 | FFAR1 (0.54) | MTNR1AFFAR1MAPTGAAALDH1A1 | |
| SCHEMBL28720097 | 0.89 | FFAR1 (0.54) | MTNR1AFFAR1MAPTGAAALDH1A1 | |
| SCHEMBL7199006 | 0.85 | MTNR1A (0.60) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL9208736 | 0.85 | MTNR1A (0.60) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL9206095 | 0.85 | MTNR1A (0.60) | MTNR1AFFAR1MAPTGAAALOX5 | |
| SCHEMBL28714659 | 0.84 | FFAR1 (0.50) | MTNR1AFFAR1MAPTGAAPOLB | |
| SCHEMBL28937417 | 0.84 | FFAR1 (0.50) | MTNR1AFFAR1MAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110092774-B | Aromatic propionic acid derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-04-08 | — | — | CN | disclosed |
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-0839145-B1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| US-5935973-A | AFFINITY FOR 5-HT1A, ALPHA1, ALPHA2 AND/OR D2 RECEPTORS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS, PSYCHOSES, DYSKINESIAS, PARKINSON'S DISEASE, HYPOTENSIVE AGENTS, TOURETTE'S SYNDROME, OBSESSIVE-COMPULSIVE BEHAVIOUR, PANIC ATTACKS, SOCIAL PHOBIAS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
| EP-0565732-B1 | BENZODIOXANE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-01-14 | — | — | EP | disclosed |
| US-5480905-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0565732-A1 | BENZODIOXANE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4539413-A | Preparation of 3-amino-1-[(1,4-benzodioxan)-2-yl-methoxy]-2-propanols | PIERRE FABRE S.A. (FR) | 1985-09-03 | — | — | US | disclosed |
| US-4456614-A | HYPOTENSIVE, AND ANTIARRHYTHMIA AGENT | PIERRE FABRE S.A. (FR) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | MTNR1A 73/4885FFAR1 2523/4885MAPT 1167/4885 |
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885FFAR1 612/4885MAPT 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.